-
1
Neuropathic pain (NP) arises from injury to the somatosensory nervous system and affects 3–17% of the global population.
-
2
Glial cells, including microglia and astrocytes, play active roles in the initiation and maintenance of NP, shifting focus from a neuron-centric model.
-
3
Glial heterogeneity is characterized by spatial, temporal, phenotypic, and molecular diversity, influencing NP mechanisms and treatment responses.
-
4
Emerging therapies targeting specific glial subpopulations, such as P2X4 receptor antagonists, show promise in treating NP beyond traditional approaches.
-
5
Understanding glial cell diversity is crucial for identifying novel therapeutic targets and developing precise, stage-tailored treatment strategies for NP.
